432 related articles for article (PubMed ID: 26923259)
1. Fosfomycin: Resurgence of an old companion.
Sastry S; Doi Y
J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
[TBL] [Abstract][Full Text] [Related]
2. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
Stock I
Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
[TBL] [Abstract][Full Text] [Related]
3. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
Reffert JL; Smith WJ
Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
[TBL] [Abstract][Full Text] [Related]
5. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
Seroy JT; Grim SA; Reid GE; Wellington T; Clark NM
J Antimicrob Chemother; 2016 Sep; 71(9):2563-8. PubMed ID: 27246234
[TBL] [Abstract][Full Text] [Related]
6. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
7. Fosfomycin: Mechanism and Resistance.
Silver LL
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28062557
[TBL] [Abstract][Full Text] [Related]
8. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M
Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943
[TBL] [Abstract][Full Text] [Related]
9. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.
Shorr AF; Pogue JM; Mohr JF
Expert Rev Anti Infect Ther; 2017 Oct; 15(10):935-945. PubMed ID: 28901793
[TBL] [Abstract][Full Text] [Related]
10. Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide.
Trinh TD; Smith JR; Rybak MJ
Pharmacotherapy; 2019 Nov; 39(11):1077-1094. PubMed ID: 31487056
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.
Giancola SE; Mahoney MV; Hogan MD; Raux BR; McCoy C; Hirsch EB
Chemotherapy; 2017; 62(2):100-104. PubMed ID: 27788499
[TBL] [Abstract][Full Text] [Related]
12. Fosfomycin: an old--new antibiotic.
Raz R
Clin Microbiol Infect; 2012 Jan; 18(1):4-7. PubMed ID: 21914036
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.
Roussos N; Karageorgopoulos DE; Samonis G; Falagas ME
Int J Antimicrob Agents; 2009 Dec; 34(6):506-15. PubMed ID: 19828298
[TBL] [Abstract][Full Text] [Related]
14. ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.
Burgos RM; Rodvold KA
Future Microbiol; 2019 Apr; 14():461-475. PubMed ID: 30854892
[TBL] [Abstract][Full Text] [Related]
15. [Fosfomycin: past, present and future].
Baylan O
Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
[TBL] [Abstract][Full Text] [Related]
16. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Wilson DT; May DB
Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
[TBL] [Abstract][Full Text] [Related]
18. Fosfomycin.
Falagas ME; Vouloumanou EK; Samonis G; Vardakas KZ
Clin Microbiol Rev; 2016 Apr; 29(2):321-47. PubMed ID: 26960938
[TBL] [Abstract][Full Text] [Related]
19. Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?
Dimopoulos G; Koulenti D; Parker SL; Roberts JA; Arvaniti K; Poulakou G
Expert Rev Anti Infect Ther; 2019 Mar; 17(3):201-210. PubMed ID: 30668931
[TBL] [Abstract][Full Text] [Related]
20. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?
Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E
J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
